本文内容来自Cell Press合作期刊The Innovation第五卷第六期发表的Review文章“Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations” (投稿 ...

Biomarker-informed therapeutic decision-making is the standard of care for malignancies with targetable genetic alterations, including BRAF mutations. It is crucial to ensure clear and consistent ...

Nat Clin Pract Endocrinol Metab. 2006;2(4):180-181. The fact that PTC is associated with mutually exclusive alterations to MAPK pathway effectors offers intriguing therapeutic opportunities. Ras ...

FDA approved for the treatment of metastatic melanoma harboring activating BRAF mutations in August, 2011. Vemurafenib is metabolized by cytochrome P450 isoenzymes (predominantly CYP3A4 ...

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

The identification of the BRAF V600E mutation in certain malignant GT cases offers a promising therapeutic target. In their paper, researchers Marta Arregui, Antonio Calles, María del Mar Galera ...

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.

The data suggest that the three-drug combination should replace chemotherapy for one in seven patients with metastatic colorectal cancer who have a BRAF mutation, according to lead investigator ...